403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Kinaxis
(MENAFN- Baystreet) 10:06 AM EST - Kinaxis : Announced that Swedish Orphan Biovitrum AB (Sobi), a leading international biopharmaceutical company, has elected to implement the Kinaxis Maestro® platform to facilitate end-to-end collaboration across its partner network, enable data-driven decisions and support the delivery of critical therapies to patients with rare diseases. Kinaxis
shares T are trading up $0.30 at $179.30.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Financewire And Tipranks Partner To Redefine Financial News Distribution
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Reaches 50% Completion In Phase 6
- Stonehaven Circle Marks 13Th Anniversary With Hadrian Colwyn Leading Calvio Ailegacyx Innovation
- Citadel Launches Suiball, The First Sui-Native Hardware Wallet
- Motif AI Enters Phase Two Of Its Growth Cycle
- Dubai At The Centre Of Global Finance: Forex Expo 2025 Redefines The Trading Landscape
More Story
Comments
No comment